ITW

DOCKET NO.: AM100638/WYNC-1027

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Elokdah, et al. Confirmation No.: 4928

Application No.: 10/731,290 Group Art Unit: 1614

Filing Date: December 9, 2003 Examiner: Golam M. Shameem

For: Substituted Dihydropyrano Indole-3,4-Dione Derivatives As Inhibitors Of

Plasminogen Activator Inhibitor-1 (PAI-1)

EXPRESS MAIL LABEL NO: EL 999319295 US

DATE OF DEPOSIT: December 8, 2005

EL999319295US

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

	before the mailing date of a first Office Action after the filing of request for
	continued examination under § 1.114, no additional fee is required.
	In accordance with § 1.97(c), this Information Disclosure Statement is being
	filed after the period set forth in § 1.97(b) above but before the mailing date of
	either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or
	before an action that otherwise closes prosecution in the application, therefore:
	Certification in Accordance with § 1.97(e) is attached; or
	The fee of \$180.00 as set forth in § 1.17(p) is attached.
	In accordance with § 1.97(d), this Information Disclosure Statement is being
	filed after the mailing date of either a Final Action under § 1.113 or a Notice
	of Allowance under § 1.311 but before, or simultaneously with, the payment
	of the Issue Fee, therefore included are: Certification in Accordance with §
	1.97(e); and the submission fee of $\underline{\$180.00}$ as set forth in $\S 1.17(p)$.
\boxtimes	Copies of reference numbers 96-115 listed on the attached Form PTO-1449
	are enclosed herewith.
\boxtimes	Copies of reference numbers 57-95 listed on the attached Form PTO 1449 are
	not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).
	Copies of references - are not being submitted because
	they were previously cited by or submitted to the U.S. Patent and
	Trademark Office in patent application number , filed for
	which a claim for priority under 35 U.S.C. § 120 has been made in the
	instant application.

DOCKET NO.: AM100638/WYNC-1027-3-

PATENT

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: December 8, 2005

Leslie E. Aberman Registration No. 54,836

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

© 2005 WW



Form	PT	O-1	449	Mo	dified
------	----	------------	-----	----	--------

List of Patent and Publications Cited by Applicant (Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

Docket No. AM100638/WYNC-1027

Application No. 10/731,290

Applicant Elokdah, et al.

Filing Date December 9, 2003 Group 1614

Confirmation No.

4928

U. S. PATENT DOCUMENTS

Examiner		Document	Data	N		G 1
Initial	+	No.	Date	Name	Class	Subclass
	57	3,026,325	03/20/62	Heinzelman et al.	548	496
	58	3,476,770	11/04/69	Scherrer	548	494
	59	3,557,142	01/19/71	Bell	548	516
	60	4,478,819	10/23/84	Hercelin et al.	424	457
	61	4,851,406	07/25/89	Martens et al.	514	217.04
	62	5,164,372	11/17/92	Matsuo et al.	514	19
	63	5,420,289	05/30/95	Musser et al.	548	159
	64	5,482,960	01/09/96	Berryman	514	414
	65	5,502,187	05/26/96	Ayer et al.	544	117
	66	5,541,343	07/30/96	Himmelsbach et al.	514	424
	67	5,859,044	01/12/99	Dow et al.	514	419
	68	6,166,069	12/26/00	Malamas et al.	514	469
	69	6,232,322	05/15/01	Malamas et al.	514	303
	70	6,479,524	11/12/02	Priepke et al.	514	352
•	71	6,599,929	07/29/03	Cho et al.	514	415
	72	2003/0013732 A1	01/16/03	Elokdah	514	301
	73	2003/0018067 A1	01/23/03	Elokdah et al.	514	469
	74	2003/0125371 A1	07/03/03	Elokdah et al.	514	419
	75	2004/0116488 A1	06/17/04	Jennings et al.	514	374
	76	2004/0116504 A1	06/17/04	Elokdah et al.	514	419
	77	2004/0122070 A1	06/24/04	Jennings	514	374
	78	2004/0138283 A1	07/15/04	Jennings et al.	514	414
	79	2005/0070584 A1	03/31/05	Havran et al.	514	357
	80	2005/0070585 A1	03/31/05	Elokdah et al.	514	364

EXAMINER	DATE CONSIDERED

Docket No. Application No. Form PTO-1449 Modified 10/731,290 AM100638/WYNC-1027 List of Patent and Publications **Applicant** Cited by Applicant Elokdah, et al. (Use several sheets if necessary) U.S. Department of Commerce Filing Date Group Patent and Trademark Office December 9, 2003 1614 Confirmation No.

U. S. PATENT DOCUMENTS

4928

Examiner		Document				
Initial		No.	Date	Name	Class	Subclass
	81	2005/0070587 A1	03/31/05	Elokdah et al.	514	381
	82	2005/0070592 A1	03/31/05	Gundersen	514	415
	83	2005/0096377 A1	05/05/05	Hu	514	419
	84	2005/0113428 A1	05/26/05	Gopalsamy et al.	514	364
	85	2005/0113438 A1	05/26/05	Hu et al.	514	414
	86	2005/0113439 A1	05/26/05	Hu	514	414
	87	2005/0119296 A1	02/06/05	Elokdah et al.	514	300
	88	2005/0119326 A1	06/02/05	Havran et al.	514	414
	89	2005/0119327 A1	06/02/05	Hu	514	414
	90	2005/0215626 A1	09/29/05	Havran et al.	514	469
	91	S.N. 10/947,710	09/23/04	Commons et al.		
	92	S.N. 10/947,711	09/23/04	Gopalsamy et al.		
	93	S.N. 11/208,777	08/22/05	Commons et al.		
	94	S.N. 11/208,772	08/22/05	Commons		
	95	S.N. 11/208,775	08/22/05	Commons et al.		

EXAMINER	DATE CONSIDERED

Docket No. Application No. Form PTO-1449 Modified 10/731,290 AM100638/WYNC-1027 List of Patent and Publications Applicant Cited by Applicant Elokdah, et al. (Use several sheets if necessary) U.S. Department of Commerce Filing Date Group1614 Patent and Trademark Office December 9, 2003 Confirmation No. 4928

FOREIGN PATENT DOCUMENTS

Examiner					Trar	slation
Initial		Document No.	Date	Country	YES	NO
	96	00/64876 A1	11/02/00	wo		
	97	00/64888 A1	11/02/00	wo		
	98	94/13637 A1	06/23/94	wo	X abstract	
	99	03/000253 A1	01/03/03	wo		
	100	0 759 434 A1	02/26/97	EP		
	101	0 822 185 A1	02/04/98	ЕР		
	102	3147276 A1	06/09/83	DE	X abstract	
	103	2 799 756 A1	04/20/01	FR		X
	104	2 244 499 A1	04/18/75	FR		X
	105	2 777 886 A1	10/29/99	FR	X abstract	
						

	EXAMINER	·	DATE CONSIDERED	
--	----------	---	-----------------	--

Form PTO	-1449 Modified	Docket No. AM100638/WYNC-1027	Application No. 10/731,290	
Cited b	t and Publications by Applicant sheets if necessary)	Applicant Elokdah, et al.		
	nent of Commerce Trademark Office	Filing Date December 9, 2003	Group 1614	
		Confirmation No. 4928		
OTHE	R DOCUMENTS (Includ	ling Author, Title, Date, Pe	rtinent Pages, Etc.)	
106			or torsional activation of amide	
107		Eur. J., January 25, 2003, 9 hemistry of Bacteria," Journ 227		
108				
Dillard R. D. et al., "Indole Inhibitors of Hu Phospholipase A ₂ 1. Indole-3-Acetamides" American Chemical Society, 39(26), 5119-			ournal of Medicinal Chemistry,	
110	Hipskind, P. A. et al., "P	otent and selective 1,2,3-trisom, 1997, 40(23), 3712-3714	ubstituted indole NPY Y-1	
111				
112	 Malamas, M. S. et al., "Antihyperglycemic activity of new 1,2,4-oxadiazolidine-diones," Eur. J. Med. Chem., 2001, 36, 31-42 Malamas, M.S. et al. "Novel benzofuran and benzothiophene biphenyls as inhibit of protein tyrosine phosphatase 1B with antihyperglycemic properties," Journal Medicinal Chemistry, April 6, 2000, 43(7), 1293-1310 			
113				
114	Moody et al., CA 120:298300, 1994			
115	Shengeliya, M. S. et al., "N-Glycosides of 5-amino-2-(ethoxycarbonyl)indole," Zhurnal Organicheskoi Khimii, 1986, 22(9),1868-1873			

EXAMINER	DATE CONSIDERED